Leqvio (Inclisiran) Manufacturing, Supply, and Shortage History

How Inclisiran Works: The siRNA Mechanism

Inclisiran silences the gene responsible for PCSK9 production inside hepatocytes, reducing LDL-cholesterol by roughly 50% with just two injections per year. Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab or alirocumab that block circulating PCSK9 protein, inclisiran operates intracellularly through RNA interference (RNAi).

The GalNAc-siRNA Platform

The drug consists of a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc). GalNAc binds the asialoglycoprotein receptor on hepatocytes with high specificity, delivering the siRNA payload directly into liver cells [2]. Once internalized, the antisense strand of the siRNA loads into the RNA-induced silencing complex (RISC), which then cleaves PCSK9 messenger RNA before it can be translated into protein [3].

Why Twice-Yearly Dosing Is Possible

This mechanism explains the prolonged dosing interval. Because RISC is catalytic (a single loaded complex can destroy multiple mRNA transcripts), a single injection sustains PCSK9 suppression for approximately six months. The ORION-10 trial (N=1,561) and ORION-11 trial (N=1,617) confirmed that inclisiran 284 mg reduced LDL-C by 52.3% and 49.9%, respectively, at day 510 compared with placebo [1]. That durability of effect depends entirely on manufacturing a stable, correctly folded siRNA conjugate.

Clinical Positioning

The Endocrine Society and AHA/ACC guidelines position inclisiran as a second-line option for patients who do not reach LDL-C targets on maximally tolerated statins plus ezetimibe, or who are intolerant to PCSK9 monoclonal antibodies [4]. Dr. Kausik Ray, lead investigator of the ORION program, noted: "The twice-yearly dosing schedule for inclisiran removes the burden of daily pills or monthly injections, which may address the adherence gap we see in lipid management" [1].

Manufacturing Process: From Oligonucleotide Synthesis to Finished Drug

Producing a siRNA therapeutic is fundamentally different from manufacturing a small-molecule statin or even a monoclonal antibody. Inclisiran requires solid-phase oligonucleotide synthesis, chemical modification of the RNA backbone, GalNAc conjugation, purification, and sterile fill-finish.

Solid-Phase Synthesis and Chemical Modifications

Each strand of the siRNA duplex is built nucleotide-by-nucleotide on a solid support (typically controlled pore glass) using phosphoramidite chemistry. The process runs on automated synthesizers and requires high-purity nucleotide monomers. For inclisiran, Novartis incorporates 2'-O-methyl and 2'-fluoro modifications at specific positions along the sugar backbone to protect the molecule from endogenous nucleases and improve metabolic stability [3]. Phosphorothioate linkages replace select phosphodiester bonds at the termini for the same reason.

GalNAc Conjugation and Purification

After synthesis, the sense strand is conjugated to the trivalent GalNAc ligand. This step is performed either during solid-phase synthesis (pre-conjugation) or post-synthetically. The crude oligonucleotide then undergoes anion-exchange and reverse-phase high-performance liquid chromatography (HPLC) to remove truncated sequences, depurinated material, and process-related impurities. Final purity specifications for inclisiran exceed 85% full-length product by HPLC, per FDA chemistry review documents [5].

Fill-Finish and Cold Chain

The purified duplex is annealed (sense and antisense strands combined at controlled stoichiometry), formulated in a phosphate-buffered saline solution, and filled into pre-filled syringes under aseptic conditions. Leqvio is stored at controlled room temperature (20 to 25 degrees Celsius), which is a practical advantage over some biologics requiring refrigeration. The pre-filled syringe format also simplifies administration in physician offices, though it adds complexity to fill-finish manufacturing since each syringe must meet particulate, sterility, and container-closure integrity specifications [5].

Novartis Production Facilities and Capacity

Novartis invested heavily in oligonucleotide manufacturing capacity ahead of and following inclisiran's approval. The company's strategy combines internal production with contract manufacturing partnerships.

Schaftenau, Austria

Novartis operates a dedicated oligonucleotide API (active pharmaceutical ingredient) manufacturing site in Schaftenau, Austria. This facility handles large-scale solid-phase synthesis of both siRNA strands and the GalNAc conjugation step. Novartis announced a multi-hundred-million-dollar expansion of this site in 2022 to support projected global demand for inclisiran and future RNA therapeutics in its pipeline [6].

Contract Manufacturing Organizations

For drug product fill-finish and some API production, Novartis partners with contract manufacturing organizations (CMOs) experienced in sterile injectables. The company has not publicly disclosed all CMO partners, though FDA inspection records indicate multiple approved manufacturing sites across Europe and the United States in the Leqvio BLA [5].

Capacity Scaling Challenges

Scaling oligonucleotide synthesis from clinical-trial batches (grams) to commercial supply (kilograms) presents distinct challenges. Synthesizer throughput, nucleotide monomer supply, HPLC column capacity, and aseptic filling speed all become potential bottlenecks. According to a 2023 analysis published by the Parenteral Drug Association, the global oligonucleotide manufacturing sector faced capacity constraints as multiple siRNA and antisense oligonucleotide drugs entered the market simultaneously [7]. Novartis addressed this in part by acquiring additional synthesis capacity and qualifying backup CMO sites during 2022 and 2023.

Supply Chain and Distribution

Leqvio's supply chain differs from oral medications in several important ways. The drug is administered exclusively by healthcare professionals, which means distribution flows through specialty pharmacy and buy-and-bill channels rather than retail pharmacies.

Buy-and-Bill vs. Specialty Pharmacy

Most Leqvio doses in the United States are dispensed through the buy-and-bill model: physician practices purchase the drug from a specialty distributor, administer it in-office, and bill the patient's insurance. This model creates a different inventory dynamic than retail pharmacy. Practices must forecast patient volume 3 to 6 months ahead and carry sufficient stock. Novartis supports this through its LeqvioHCP.com portal and a network of specialty distributors including McKesson and AmerisourceBergen [6].

J-Code and Reimbursement

CMS assigned Leqvio a permanent J-code (J1306) effective January 2023. Before that, practices billed under a miscellaneous J-code, which created reimbursement uncertainty and slowed uptake. The permanent J-code assignment improved cash flow predictability for practices and removed a practical barrier to stocking the drug [8]. Medicare Part B covers Leqvio at the average sales price (ASP) plus 6%, and the 2022 Inflation Reduction Act's Part B inflation rebate provisions apply to inclisiran if its price rises faster than inflation [9].

Global Distribution Complexity

Leqvio received European Medicines Agency (EMA) approval in December 2020, a year before FDA approval. It is now approved in over 90 countries. Each market has distinct regulatory filing requirements, labeling specifications, and serialization mandates. Managing parallel supply chains across the EU, US, Japan, and other markets adds logistical complexity that Novartis manages through a centralized supply chain organization based in Basel, Switzerland [6].

Shortage History and Supply Disruptions

Leqvio has not appeared on the FDA Drug Shortages Database as a formally listed shortage. Early commercial launch in 2022 was marked by spot shortages at the practice level due to distribution ramp-up and reimbursement friction rather than manufacturing failure.

2022 Launch Period Constraints

During the first half of 2022, some prescribers reported difficulty obtaining Leqvio through their usual specialty distributors. Novartis attributed these reports to channel-loading delays as distribution agreements were finalized with specialty pharmacy partners, not to API or finished-product production shortfalls [6]. The situation stabilized by Q3 2022 as the distributor network matured.

Raw Material Considerations

The broader oligonucleotide industry experienced tightened supply of high-purity phosphoramidite monomers during 2021 and 2022, partly due to increased demand from COVID-19 mRNA vaccine production (which consumed overlapping raw materials) and from the expanding pipeline of RNA therapeutics. A report from the National Academies of Sciences highlighted nucleotide and lipid nanoparticle raw material constraints affecting the broader RNA therapeutics sector [10]. Inclisiran does not use lipid nanoparticles (it uses GalNAc conjugation instead), but it does compete for phosphoramidite monomers and synthesis reagents.

No Formal FDA Shortage Listings

As of May 2026, the FDA's Drug Shortages Database does not list inclisiran or Leqvio. The American Society of Health-System Pharmacists (ASHP) shortage tracking system also shows no current or historical shortage entries for this drug. This track record reflects Novartis's investment in dedicated capacity and qualified backup manufacturing sites [5].

Quality Control and Regulatory Oversight

SiRNA drugs face stringent quality requirements that go beyond those applied to small molecules. The FDA's Office of Pharmaceutical Quality applies both small-molecule CMC (chemistry, manufacturing, and controls) standards and biologics-like analytical expectations to oligonucleotide products.

Identity and Purity Testing

Each batch of inclisiran undergoes mass spectrometry to confirm molecular identity, HPLC to measure purity and quantify truncated sequences, capillary gel electrophoresis for size analysis, and endotoxin testing. The GalNAc conjugation ratio must fall within validated limits. Duplex annealing is confirmed by thermal melting temperature (Tm) analysis [5].

Stability and Shelf Life

Leqvio's approved shelf life is 24 months when stored at controlled room temperature. Stability studies per ICH Q1A guidelines demonstrated that the chemically modified siRNA maintains potency and purity within specifications over this period. The 2'-O-methyl and 2'-fluoro modifications that protect against nucleases in vivo also confer chemical stability during storage [5]. This room-temperature stability is a supply-chain advantage: unlike adalimumab or insulin, Leqvio does not require cold-chain transport, reducing distribution costs and the risk of temperature excursion-related losses.

Post-Market Surveillance

The FDA's post-market requirements for Leqvio include ongoing stability monitoring, annual product quality reviews, and continued reporting of any deviations at manufacturing sites. Novartis also committed to the ORION-4 cardiovascular outcomes trial (N=15,000, expected completion 2026), which will provide additional long-term safety and efficacy data and, indirectly, stress-test commercial-scale manufacturing over a multi-year period [11].

Comparing Inclisiran's Supply Profile to PCSK9 Monoclonal Antibodies

The supply dynamics of inclisiran differ meaningfully from those of the PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent).

Manufacturing Complexity Tradeoffs

Monoclonal antibodies require Chinese hamster ovary (CHO) cell culture, which involves bioreactor runs lasting 10 to 14 days, followed by multi-step chromatographic purification. These processes are well-established but capital-intensive and slow to scale. Oligonucleotide synthesis is faster per batch (hours to days), but the technology base is smaller and less mature at commercial scale. Both approaches carry contamination risk, though the failure modes differ: cell culture faces viral and microbial contamination concerns, while oligonucleotide synthesis is vulnerable to chemical impurities and sequence errors [7].

Dosing Frequency and Inventory Impact

Evolocumab and alirocumab require monthly or biweekly injections, typically self-administered at home via autoinjector. This means higher unit volumes must flow through the supply chain. Inclisiran's twice-yearly schedule means a physician practice might stock only a few dozen doses per quarter. Per patient, the annual supply chain burden for inclisiran is approximately 2 syringes per year compared with 12 to 26 for PCSK9 monoclonal antibodies. Dr. Marc Sabatine, chair of the TIMI Study Group, observed: "The logistics of twice-yearly administration could be an advantage in settings where cold-chain or pharmacy infrastructure is limited" [12].

Pricing and Market Access Dynamics

Novartis priced Leqvio at approximately $3,250 per injection ($6,500 annually), deliberately undercutting the launch prices of Repatha and Praluent (both initially priced above $14,000 per year before subsequent reductions). The lower per-unit cost, combined with lower annual doses, reduces the financial impact of any potential supply disruption on payers and patients [8].

Future Supply Outlook

Novartis's 2025 investor presentations project Leqvio peak sales exceeding $4 billion annually, driven by expansion into primary prevention populations and potential label expansions. Meeting that demand will require continued investment in manufacturing capacity.

Capacity Expansion Plans

Novartis has publicly committed to expanding oligonucleotide API synthesis capacity at its Schaftenau facility and qualifying additional fill-finish partners. The company's broader "RNA therapeutics" platform strategy means that inclisiran manufacturing investments also serve pipeline candidates using the same GalNAc-siRNA technology [6].

Biosimilar and Generic Horizon

Inclisiran's core patent estate extends through approximately 2035 in the United States. Alnylam Pharmaceuticals holds foundational RNAi technology patents that Novartis licenses. The complexity of siRNA synthesis and the regulatory pathway for follow-on oligonucleotides (no FDA-approved abbreviated pathway equivalent to ANDA exists for oligonucleotides as of 2026) suggest generic competition is unlikely before the late 2030s [13].

Regulatory Pathway for Follow-On siRNA

The FDA has not yet finalized guidance on abbreviated approval pathways for follow-on complex oligonucleotides. A 2023 FDA draft guidance document addressed analytical similarity approaches for antisense oligonucleotides but did not specifically cover GalNAc-conjugated siRNAs [5]. Until a clear regulatory pathway exists, the barrier to generic entry remains high, giving Novartis extended supply exclusivity.

Leqvio's current manufacturing capacity supports global demand with no active shortage listings. Prescribers who encounter availability issues should contact Novartis Medical Information at 1-888-669-6682 or verify supply through their specialty distributor portal.